Editorial and Publication Policy

Peer Review Policy

JPIMC follows a rigorous double-blind peer review process to ensure objectivity, originality, and scientific merit.

  • Manuscripts are first screened by the editorial office for compliance with journal scope, formatting, and ethical standards.

  • Eligible manuscripts are assigned to subject experts for review.

  • At least two independent reviewers evaluate the manuscript on originality, methodology, ethical compliance, and contribution to the field.

  • The Editorial Board makes the final decision (acceptance, revision, or rejection) based on reviewers’ feedback.

Editorial Independence

All editorial decisions at JPIMC are made independently, free from external influence of sponsors, advertisers, or institutional affiliations.

  • Decisions are based solely on scientific merit, relevance, and ethical compliance.

  • Editors are required to declare any potential conflicts of interest and recuse themselves where appropriate.

Authorship Policy

JPIMC follows the ICMJE criteria for authorship. Authorship is restricted to individuals who have made substantial contributions to:

  1. The conception or design of the work, or the acquisition, analysis, or interpretation of data.

  2. Drafting or critically revising the manuscript.

  3. Final approval of the version to be published.

  4. Accountability for all aspects of the work.

Contributors not meeting authorship criteria should be acknowledged appropriately.

Ethical Standards

  • Human Studies: Manuscripts must include evidence of approval by an Institutional Review Board (IRB) or Ethics Committee, and confirmation of informed consent where applicable.

  • Animal Studies: Authors must follow internationally accepted standards for the humane treatment of animals.

  • Clinical Trials: Must be registered in a recognized clinical trial registry (e.g., ClinicalTrials.gov).

  • Conflicts of Interest: All authors, reviewers, and editors must disclose potential conflicts.

JPIMC fully complies with the recommendations of COPE, ICMJE, and WAME for ethical publishing.

Plagiarism and Research Misconduct

  • All manuscripts are screened using plagiarism detection software.

  • Plagiarism, data fabrication, falsification, duplicate submission, or redundant publication will result in immediate rejection.

  • If misconduct is identified after publication, the journal will issue a correction, expression of concern, or retraction in accordance with COPE guidelines.

Data Sharing and Reproducibility

  • Authors are encouraged to provide datasets, protocols, and supplementary material to support reproducibility and transparency.

  • Where possible, data should be deposited in reputable repositories with appropriate citations.

Copyright and Licensing

  • All articles are published under the Creative Commons Attribution–NonCommercial 4.0 International License (CC BY-NC 4.0).

  • Authors retain copyright of their work.

  • Articles may be shared and reproduced for non-commercial purposes, provided proper citation is given.

  • Commercial use requires prior written permission.

Publication Frequency

JPIMC is published quarterly (January–March, April–June, July–September, October–December).
Special issues may be released to address emerging topics of public health or medical importance.

Corrections and Retractions

JPIMC maintains a transparent process for handling post-publication issues:

  • Corrections: Issued when minor errors do not compromise the validity of the work.

  • Expressions of Concern: Published when serious issues are under investigation.

  • Retractions: Issued for confirmed cases of serious ethical breaches or invalid results.

Diversity and Inclusion

JPIMC is committed to promoting diversity, equity, and inclusion in research publishing.

  • Manuscripts are evaluated without regard to gender, ethnicity, nationality, or institutional affiliation.

  • The journal actively encourages submissions from early-career researchers and underrepresented groups.

Privacy and Confidentiality

  • Information obtained during submission, peer review, or publication is kept strictly confidential.

  • Reviewer identities remain anonymous under the double-blind policy.

  • Patient confidentiality must always be preserved—identifiable data should not be published without explicit written consent.